Overview

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Almonertinib versus placebo in patients with epidermal growth factor receptor mutation-positive (EGFRm+) stage II-IIIB non-small cell lung cancer (NSCLC), following complete tumor resection with or without adjuvant chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.